Demeclocycline |
Catalog No.GF14710 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 127-33-3
Sample solution is provided at 25 µL, 10mM.
Demeclocycline (0-100 渭M; 24 h) treatment reduces AQP2 abundance in mpkCCD cells[3].
Demeclocycline (10 渭M; 24 h) treatment promotes the activity of monocytes and macrophages[4].
Demeclocycline (1-10 渭M; 72 h) treatment directly affects the growth of brain tumorinitiating cells[4].
Demeclocycline (Intraperitoneal injection; 40 mg/kg; once daily; 48 h) treatment results in a significant reduction of hyponatremia and a significant correction of the hypoosmolality, and is not nephrotoxic[3].
[1]. I Chopra, et al. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother. 1992 Mar;29(3):245-77.
[2]. D Schnappinger, et al. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol. 1996 Jun;165(6):359-69.
[3]. Marleen L A Kortenoeven, et al. Demeclocycline attenuates hyponatremia by reducing aquaporin-2 expression in the renal inner medulla. Am J Physiol Renal Physiol. 2013 Dec 15;305(12):F1705-18.
[4]. Susobhan Sarkar, et al. Demeclocycline Reduces the Growth of Human Brain Tumor-Initiating Cells: Direct Activity and Through Monocytes. Front Immunol. 2020 Feb 21;11:272.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *